Navigation Links
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Date:12/8/2008

roducts, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... Aug. 26, 2015  The Diabetes Research Institute ... of Miami Miller School of Medicine, announced today ... to test for the first time a novel ... This FDA approved Phase I/II study builds upon ... is an important first step toward the development ...
(Date:8/26/2015)... 26, 2015 Intrexon Corporation (NYSE: XON ... closing of its previously announced public offering of common ... of their option to purchase an additional 731,707 shares ... $41.00 per share.  The exercise of the underwriters, option ... sold by Intrexon to 5,609,756 shares and increased the ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... August 26, 2015 Despite ... fueling the optimism in biotech,s forecast is the ... life sciences advancements.  Active biotechnology & healthcare companies ... Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ... Raptor Pharmaceutical Corp. (NASDAQ: RPTP ) and ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... Alfacell Corporation,(Nasdaq: ACEL ) today reported its financial ... 31, 2008., The company recorded a net loss ... common share, for the fourth fiscal quarter ended,July 31, ... or $0.05 per,basic and diluted common share, for the ...
... Oct. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company ... ("PRC"), announced today that it,started production at Peng ... that it acquired, on October 14, 2008., ...
... and facilitate new R&D,collaborations-, WASHINGTON, Oct. 14 ... that the Bill & Melinda Gates Foundation has,expanded ... further engage,biotechnology industry innovation to create new medicines ... million grant will help BVGH build,the market case ...
Cached Biology Technology:Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 2Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 4Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 5China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 2China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 3BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World 2
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 La ... www.icg-10.org ) sera organisée par le BGI du ... Shenzhen en Chine. La ... son inauguration en 2006, l,ICG est devenue l,une ... le domaine des « omiques » et c,est aussi la ...
(Date:7/31/2015)... 31, 2015 The 10 th International Conference ... BGI from October 22-25, 2015, in Shenzhen , ... is celebrating its 10 th anniversary this year. Since its ... most influential annual meetings in the ,omics, fields, and is ... ICG-10 focuses on recent breakthroughs and advances ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... N.Y. (Tuesday, April 1, 2008) Identifying genes ... the mouse used to be a monumental task. ... it effective for even the smallest laboratories. This ... ( www.cshprotocols.org/TOCs/toc4_08.dtl ) highlights a method for screening the ...
... Challenges and Promise of Cell-Based Therapies is ... medicine using stem cells. The opening plenary session will ... will be followed by four plenary sessions that will ... musculoskeletal, and metabolic diseases and disorders. It will close ...
... 2008Biotechnology companies are focusing on the development of ... diagnostic tests for cancer, reports Genetic Engineering and ... forward, a much stronger and targeted emphasis on ... in the April 1 issue of GEN ( ...
Cached Biology News:Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution 2Challenges and promise of cell-based therapies 2
Request Info...
... FLA-7000 excels at fluorescent and radioisotopic image ... features four easy-to-access filters (filters of Y520, ... Imaging Plates) for upgrading flexibility. In addition, ... four kinds of excitation laser beams. ,The ...
... Labeling Kit generates labeled cDNA for use ... is made via a reverse transcription from ... Unlike other methods, there are no unnatural ... reaction. This unmodified cDNA is then labeled ...
... An easy-to-use solution that enables fully automated ... 400 Hybridization Station has been designed to ... the throughput necessary to perform a wide ... performed in the range 485C; denaturations of ...
Biology Products: